Orchid Cellmark Posts Flat Q4 Revenues | GenomeWeb

This article has been updated to include a stock quote.

NEW YORK (GenomeWeb News) – Orchid Cellmark today reported flat fourth-quarter revenues as its profit declined on higher costs for performing DNA testing services.

The Princeton, NJ-based firm brought in revenues of $15 million for the three months ended Dec. 31 compared to revenues of $14.9 million in the fourth quarter of 2006.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.